Prime Medicine Inc (PRME)

$3.33 -0.22 (-6.20%)
Market Cap 477.74M
Revenue (ttm) 2.98M
Net Income (ttm) -195.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,573.15%
Debt to Equity Ratio 0.00
Volume 4,111,600
Avg Vol 3,956,534
Day's Range N/A - N/A
Shares Out 134.57M
Stochastic %K 4%
Beta 2.64
Analysts Strong Sell
Price Target $6.28

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 465 0013
Address:
60 First Street, Cambridge, United States
arg195
arg195 Nov. 14 at 3:41 PM
$PRME the prophecy is nearing @sogenerous
1 · Reply
JasonCO
JasonCO Nov. 14 at 2:58 PM
$PRME
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 14 at 2:56 PM
$PRME Mcnulty indicator
1 · Reply
FredGS
FredGS Nov. 14 at 2:52 PM
$PRME https://youtu.be/1J3uj2wqPPA?si=K7nPiFLCFCARX2qv
0 · Reply
PorkchopSquats
PorkchopSquats Nov. 14 at 2:40 PM
$PRME YALL CANT SEE THIS BUT HELL YEAH FINALLY BUCKING THE MARKET FOR LIKE FIVE MINUTES LFGGGGGGGGG
0 · Reply
FredGS
FredGS Nov. 14 at 2:40 PM
$PRME Green!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 14 at 1:45 PM
Enter: $PRME Calls Strike Price: $4 Expiry Date: DEC 19 2025 Buy in Price: $0.34 - $0.35 Sell Price: $0.54 Profit : +60% (Turn every $1 into $1.60) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 14 at 1:01 PM
$PRME Daily Deion
0 · Reply
PorkchopSquats
PorkchopSquats Nov. 14 at 11:41 AM
$PRME Where ST board?
1 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 14 at 5:03 AM
$PRME We are so back
1 · Reply
Latest News on PRME
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 12, 2025, 2:51 PM EST - 1 day ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 3 days ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 10:21 AM EST - 7 days ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 7 days ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Nov 3, 2025, 8:01 AM EST - 11 days ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 30, 2025, 4:01 PM EDT - 14 days ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Prime Medicine to Participate in Upcoming Investor Conferences

Oct 7, 2025, 8:00 AM EDT - 5 weeks ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 5:38 PM EDT - 2 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 2 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Aug 1, 2025, 4:01 PM EDT - 3 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 9:33 PM EDT - 3 months ago

Prime Medicine Announces Pricing of Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 30, 2025, 4:01 PM EDT - 3 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 8:10 AM EDT - 4 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 16, 2025, 7:00 AM EDT - 4 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Jul 7, 2025, 4:45 PM EDT - 4 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:31 AM EDT - 6 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 19, 2025, 8:30 AM EDT - 6 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 6 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Mar 18, 2025, 7:00 AM EDT - 8 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 28, 2025, 8:00 AM EST - 9 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 9 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Jan 30, 2025, 12:26 PM EST - 10 months ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Prime Medicine Unveils Strategically Focused Pipeline

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 20, 2024, 4:01 PM EST - 1 year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 28, 2024, 8:11 AM EST - 1 year ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 25, 2024, 8:00 AM EST - 1 year ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

Dec 1, 2023, 2:45 PM EST - 2 years ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

Prime Medicine to Present at Upcoming Investor Conferences

Nov 8, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Upcoming Investor Conferences

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 3, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 27, 2023, 6:00 AM EDT - 2 years ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

arg195
arg195 Nov. 14 at 3:41 PM
$PRME the prophecy is nearing @sogenerous
1 · Reply
JasonCO
JasonCO Nov. 14 at 2:58 PM
$PRME
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 14 at 2:56 PM
$PRME Mcnulty indicator
1 · Reply
FredGS
FredGS Nov. 14 at 2:52 PM
$PRME https://youtu.be/1J3uj2wqPPA?si=K7nPiFLCFCARX2qv
0 · Reply
PorkchopSquats
PorkchopSquats Nov. 14 at 2:40 PM
$PRME YALL CANT SEE THIS BUT HELL YEAH FINALLY BUCKING THE MARKET FOR LIKE FIVE MINUTES LFGGGGGGGGG
0 · Reply
FredGS
FredGS Nov. 14 at 2:40 PM
$PRME Green!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 14 at 1:45 PM
Enter: $PRME Calls Strike Price: $4 Expiry Date: DEC 19 2025 Buy in Price: $0.34 - $0.35 Sell Price: $0.54 Profit : +60% (Turn every $1 into $1.60) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 14 at 1:01 PM
$PRME Daily Deion
0 · Reply
PorkchopSquats
PorkchopSquats Nov. 14 at 11:41 AM
$PRME Where ST board?
1 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 14 at 5:03 AM
$PRME We are so back
1 · Reply
angelinvesting369
angelinvesting369 Nov. 14 at 1:36 AM
$PRME
0 · Reply
angelinvesting369
angelinvesting369 Nov. 14 at 1:35 AM
$PRME give me $3.X
0 · Reply
angelinvesting369
angelinvesting369 Nov. 14 at 1:33 AM
$PRME
0 · Reply
PorkchopSquats
PorkchopSquats Nov. 13 at 11:31 PM
$PRME
0 · Reply
JasonCO
JasonCO Nov. 13 at 11:20 PM
$PRME
1 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 13 at 11:15 PM
$PRME https://x.com/drmakaryfda/status/1989102420455288987?s=46
0 · Reply
FredGS
FredGS Nov. 13 at 9:55 PM
$PRME Holding long for 10 years.
0 · Reply
SteveJohnsonis
SteveJohnsonis Nov. 13 at 9:51 PM
$PRME
0 · Reply
SteveJohnsonis
SteveJohnsonis Nov. 13 at 9:44 PM
$ASTS $PRME
0 · Reply
PorkchopSquats
PorkchopSquats Nov. 13 at 9:00 PM
$PRME Another day, another big “fuck you” candle into close.
1 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 13 at 8:56 PM
$PRME it sto
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Nov. 13 at 8:34 PM
$PRME yummy crumbs
1 · Reply